Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer

The aim of the present study was to investigate the efficacy of paclitaxel following a first-line cisplatin regimen in patients with metastatic bladder cancer. The present study retrospectively evaluated the clinical effects and toxicities of second-line paclitaxel regimens following first-line cisplatin treatment in metastatic bladder cancer.

A total of 42 patients with progressing metastatic urothelial bladder cancer following cisplatin-based chemotherapy were enrolled. The patients received weekly treatment with paclitaxel (80 mg/m(2)) with a median duration of 3 months. The overall response rate, disease control rate and median progression free survival were 9.5, 45.2 and 6.4 months, respectively. Weekly paclitaxel was well-tolerated with rare grade III or IV toxicities. Second-line weekly paclitaxel treatment following first-line cisplatin-based chemotherapy is an effective and well-tolerated regimen in urothelial metastatic bladder cancer.

Molecular and clinical oncology. 2016 Mar 17 [Epub]

Spyridon Sideris, Fouad Aoun, Marc Zanaty, Nieves Chanza Martinez, Sofia Latifyan, Ahmad Awada, Thierry Gil

Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium., Department of Urology, Jules Bordet Institute, 1000 Brussels, Belgium., Data Center, Université Paris XII, 94010 Créteil, France., Medical Oncology Clinic, University Hospital of Erasme, 1070 Brussels, Belgium., Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium., Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium., Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.

Go “Beyond the Abstract”- Read an article written by the authors for UroToday.com

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe